- Sections
- C - Chimiemétallurgie
- C07K - Peptides
- C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
Détention brevets de la classe C07K 14/705
Brevets de cette classe: 15293
Historique des publications depuis 10 ans
|
759
|
943
|
1062
|
1103
|
1301
|
1271
|
1207
|
1194
|
1070
|
252
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| The Regents of the University of California | 20473 |
331 |
| The Trustees of the University of Pennsylvania | 4392 |
329 |
| The Board of Trustees of the Leland Stanford Junior University | 6593 |
213 |
| Regeneron Pharmaceuticals, Inc. | 4570 |
194 |
| Memorial Sloan-Kettering Cancer Center | 1993 |
192 |
| Board of Regents, The University of Texas System | 6018 |
164 |
| Novartis AG | 10376 |
148 |
| Immatics Biotechnologies GmbH | 1120 |
140 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2956 |
135 |
| The General Hospital Corporation | 4797 |
96 |
| Dana-Farber Cancer Institute, Inc. | 2622 |
88 |
| Autolus Limited | 265 |
85 |
| City of Hope | 1015 |
82 |
| H. Lee Moffitt Cancer Center and Research Institute, Inc. | 1007 |
78 |
| Alpine Immune Sciences, Inc. | 81 |
76 |
| Baylor College of Medicine | 986 |
74 |
| CRISPR Therapeutics AG | 363 |
71 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3339 |
71 |
| The Johns Hopkins University | 5796 |
70 |
| Lentigen Technology, Inc. | 105 |
69 |
| Autres propriétaires | 12587 |